CITF Research Results

CITF Research Results2022-09-28T09:22:35-04:00

Identification of Important genetic indicators of COVID-19 outcomes

Research carried out at the CITF-funded Biobanque québécoise de la COVID-19 (BQC19), published in PLOS Genetics by Drs. Guillaume Butler-Laporte, Brent Richards, and Vincent Mooser (McGill University), showed that those with a rare deleterious variant (disease causing variant) in the SARS-CoV-2 sensor toll-like receptor TLR7 gene (on chromosome X in the host) were associated with a 5.3-fold increase in severe disease.

November 16, 2022|General population studies|

Is one vaccine dose enough for individuals who have recovered from a SARS-CoV-2 infection?

Research stemming from the CITF-funded RECOVER study, published in Frontiers in Immunology, indicates that a two-dose primary series of vaccination is paramount for protection against COVID-19, even for those who were previously infected. Individuals who did not experience symptoms during their SARS-CoV-2 infection and had no antibodies to SARS-CoV-2 (negative serostatus) prior to vaccination show weaker immune responses to each vaccine dose than their symptomatic counterparts.

November 7, 2022|General vaccine surveillance|

Vaccine-induced immune responses are as durable in people living with HIV as in people without HIV

A CITF-funded study, published in preprint, and not yet peer-reviewed, from Mark Brockman and Zabrina Brumme (Simon Fraser University and BC Centre for Excellence in HIV/AIDS), along with Drs. Aslam Anis and Marc Romney (University of British Columbia) showed that the antibody responses induced by a third dose of COVID-19 vaccine were as durable in people living with HIV (PLWH) receiving antiretroviral therapy (ART) as in individuals without HIV. 

November 7, 2022|Higher risk due to health condition|

Health inequalities by income have persisted in Canada throughout the COVID-19 pandemic

A preprint, not yet peer-reviewed, from CITF-funded researchers Dr. Sharmistha Mishra, Ms. Huiting Ma, Dr. Sharon Straus (University of Toronto) and their Wellness Hub team, indicated that public health interventions implemented since the first wave of the COVID-19 pandemic did not sufficiently address income-related health disparities.

November 7, 2022|General population studies|

Risk factors for SARS-CoV-2 seropositivity and seroconversion among children and adolescents in Montreal

In a preprint, not yet peer-reviewed, CITF-funded researchers Drs. Kate Zinszer (University of Montreal) and Caroline Quach (University of Montreal, Research Centre of the Sainte-Justine University Hospital) identified a variety of factors that contributed to an increased risk of seropositivity and seroconversion in children and adolescents.

November 7, 2022|Pediatrics|
Go to Top